---
document_datetime: 2023-09-21 19:33:59
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/solymbic-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: solymbic-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.1526763
conversion_datetime: 2025-12-30 22:24:14.853275
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## SOLYMBIC

Procedural steps taken and scientific information after the authorisation

<!-- image -->

<!-- image -->

| Application number   | Scope                                                                                                                                                                                                                                            | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on no   | Product Information affected 3   | Summary   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|------------------------------------------------|----------------------------------|-----------|
| IG/0946              | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing Medicinal | 04/06/2018 product                  | 14/06/2018                                     | PL                               |           |
| WS/1373/G            | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.                                                                                          | 26/04/2018                          | 14/06/2018                                     | SmPC and PL                      |           |

Medicinal product no longer authorised

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH   | longer authorised                 |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------|
| WS/1358   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product                                                                                                                                                                                                                                  | 12/04/2018 n/a product no         |
| WS/1313/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the Medicinal                                                                                                  | 14/12/2017 14/06/2018 SmPC and PL |

<div style=\"page-break-after: always\"></div>

|         | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH   | longer authorised                     |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------|
| IG/0853 | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                                                                                                                                                                                                                      | 10/11/2017 14/06/2018 Annex II and no |
| WS/1182 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Submission of the final report from study/studies 20130258, an open-label, single-arm extension study to evaluate the long-term safety and efficacy of ABP 501 in subjects with moderate to severe rheumatoid arthritis, listed as a category 3 study in the RMP (MEA002). No changes of the PI are proposed; the RMP is updated accordingly (version 2.0). Medicinal         | 01/09/2017 n/a product                |

<div style=\"page-break-after: always\"></div>

| elsewhere in this Annex which involve the submission   |
|--------------------------------------------------------|
| of studies to the competent authority                  |

<!-- image -->